De Montis G M, Devoto P, Gessa G L, Meloni D, Porcella A, Saba P, Serra G, Tagliamonte A
Institute of Pharmacology and Biochemical Pathology, University of Cagliari, Italy.
Eur J Pharmacol. 1989 Aug 22;167(2):299-303. doi: 10.1016/0014-2999(89)90592-x.
[3H]SCH 23390 binding and dopamine (DA)-stimulated adenylate cyclase activity were measured in brain membrane preparations from rats chronically treated with imipramine (10 mg/kg twice daily for 14 days). [3H]SCH 23390 binding sites were decreased by 27% in the limbic system but only 14% in the striatum. The responsiveness of adenylate cyclase to DA was reduced by 38% in the limbic system but was not modified in the striatum. Concomitant treatment with alpha-methyltyrosine (alpha-MPT) (50 mg/kg daily for 14 days) prevented the imipramine-induced reduction in both [3H]SCH 23390 binding sites and the responsiveness of adenylate cyclase to DA.
在长期接受丙咪嗪治疗（每日两次，每次10毫克/千克，共14天）的大鼠的脑膜制备物中，测定了[3H]SCH 23390结合以及多巴胺（DA）刺激的腺苷酸环化酶活性。[3H]SCH 23390结合位点在边缘系统中减少了27%，但在纹状体中仅减少了14%。腺苷酸环化酶对DA的反应性在边缘系统中降低了38%，但在纹状体中未发生改变。同时给予α-甲基酪氨酸（α-MPT）（每日50毫克/千克，共14天）可防止丙咪嗪诱导的[3H]SCH 23390结合位点以及腺苷酸环化酶对DA反应性的降低。
